Endonovo Therapeutics (ENDV) Equity Ratio (2016 - 2023)
Endonovo Therapeutics has reported Equity Ratio over the past 13 years, most recently at 28.15 for Q3 2023.
- Quarterly results put Equity Ratio at 28.15 for Q3 2023, down 108.34% from a year ago — trailing twelve months through Sep 2023 was 28.15 (down 108.34% YoY), and the annual figure for FY2022 was 25.12, down 219.59%.
- Equity Ratio for Q3 2023 was 28.15 at Endonovo Therapeutics, down from 22.08 in the prior quarter.
- Over the last five years, Equity Ratio for ENDV hit a ceiling of 3.09 in Q1 2019 and a floor of 28.15 in Q3 2023.
- Median Equity Ratio over the past 5 years was 7.47 (2021), compared with a mean of 10.39.
- Biggest five-year swings in Equity Ratio: grew 11.94% in 2020 and later plummeted 219.59% in 2022.
- Endonovo Therapeutics' Equity Ratio stood at 6.26 in 2019, then increased by 11.94% to 5.51 in 2020, then crashed by 42.54% to 7.86 in 2021, then crashed by 219.59% to 25.12 in 2022, then decreased by 12.06% to 28.15 in 2023.
- The last three reported values for Equity Ratio were 28.15 (Q3 2023), 22.08 (Q2 2023), and 20.33 (Q1 2023) per Business Quant data.